ACOT8

Across TCGA pan-cancer cohorts, ACOT8 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of ACOT8’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where ACOT8 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ACOT8 is over-expressed in tumor, although a few such as KIRC and KIRP show the opposite, repressed pattern.

LIHC, HNSC, and BLCA are the cancer types where ACOT8 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ACOT8 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Male	All	+0.974	<.001	9	view →
HNSC	Male	III,IV	+0.481	.001	8	view →
BLCA	All	All	+0.483	<.001	7	view →
BRCA	All	III,IV	+0.685	<.001	6	view →
CHOL	All	All	+1.205	<.001	5	view →
KIRC	Male	All	−0.305	<.001	4	view →
LUAD	Female	All	+0.176	.011	3	view →
STAD	All	II,III,IV	+0.507	.006	2	view →
PAAD	All	All	+0.454	.026	2	view →
KIRP	Male	All	−0.326	.013	2	view →
PRAD	All	All	+0.304	.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

ACOT8–LIHC

Open the LIHC breakdown →